BlackRock Health Sciences Term (BMEZ) vs Prospect Capital (PSEC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
BlackRock Health Sciences Term (BMEZ) has outperformed Prospect Capital (PSEC) over the past year, gaining 10.6% versus a loss of 37.0%. Over five years, BMEZ leads with a -39.6% price change compared with -79.0% for PSEC. BlackRock Health Sciences Term is the larger company by market cap ($1.03 billion vs $918.2 million), about 1.1 times the size.
On valuation, BlackRock Health Sciences Term trades at a lower trailing P/E (4.9x vs 28.7x for Prospect Capital). Prospect Capital pays a dividend yielding 30.23%, while BlackRock Health Sciences Term does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEZ | PSEC |
|---|---|---|
| Share price | $16.52 | $1.72 |
| Market cap | $1.03B | $918.16M |
| 1-day change | +1.60% | -5.49% |
| YTD return | +9.77% | -33.59% |
| 1-year return | +10.58% | -37.00% |
| 5-year return | -39.58% | -78.97% |
| P/E ratio (TTM) | 4.87 | 28.67 |
| Forward P/E | — | 4.91 |
| EPS (TTM) | $3.39 | $0.06 |
| Dividend yield | 7.99% | 30.23% |
| Annual dividend | $0.00 | $0.52 |
| Net income (latest FY) | — | $153.66M |
| 52-week high | $17.25 | $3.13 |
| 52-week low | $13.70 | $1.72 |
| Distance from 52-week high | -4.23% | -45.05% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +16.28% |
| Average volume | 141.75K | 4.78M |
| Shares outstanding | 62.50M | 533.82M |
| Sector | Financial Services | Financial Services |
| Industry | Asset Management | Asset Management |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEZ has outperformed PSEC by 47.6 percentage points over the past year.
- Prospect Capital trades at a higher earnings multiple (28.7x vs 4.9x trailing P/E).
- Prospect Capital offers a meaningfully higher dividend yield (30.23% vs 7.99%).
About Prospect Capital
PSEC stock →Prospect Capital Corporation is a Private Equity, Private Debt and business development company. It specializes in middle market, lower-middle market, mature, mezzanine finance, later stage, emerging growth, leveraged buyouts, refinancing, acquisitions, recapitalizations, turnaround, growth capital, development, capital expenditures and subordinated debt tranches of collateralized loan obligations, cash flow term loans, market place lending and bridge transactions.
Financial Services · Asset Management
BMEZ vs PSEC FAQ
Which is bigger, BlackRock Health Sciences Term or Prospect Capital?
BlackRock Health Sciences Term (BMEZ) is larger, with a market capitalization of $1.03B compared with $918.16M for Prospect Capital (PSEC).
Which stock has performed better over the past year, BMEZ or PSEC?
BMEZ returned +10.58% over the past 12 months, compared with -37.00% for PSEC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMEZ or PSEC?
BMEZ has the lower trailing P/E at 4.9, versus 28.7 for PSEC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, BlackRock Health Sciences Term or Prospect Capital?
Prospect Capital has the higher yield at 30.23%, compared with 7.99% for BlackRock Health Sciences Term.
Are BlackRock Health Sciences Term and Prospect Capital in the same industry?
Yes. Both are classified in the Asset Management industry within the Financial Services sector.